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Abstract
Background: People with multiple sclerosis (MS) are increasingly using the Internet in the daily management of
their condition. They search for high-quality information in plain language, from independent sources, based on
reliable and up-to-date evidence. The Integrating and Deriving Evidence, Experiences and Preferences (IN-DEEP)
project in Italy and Australia aimed to provide people with MS and family members with an online source of
evidence-based information, starting from their information needs. This paper reports on the Italian project’s website.
Methods: Contents, layout and wording were developed with people with MS and pilot-tested. The website was
evaluated using an online 29-item questionnaire for ease of language, contents, navigation, and usefulness of
information aimed at people with MS, family members and the general population.
Results: The website (http://indeep.istituto-besta.it/) is structured in multiple levels of information. The first topic
was interferons-β for people with relapsing-remitting MS. In all, 433 people responded to the survey (276 people
with MS, 68 family members and 89 others). The mean age was 45 years, almost 90 % had a high school diploma,
about 80 % had relapsing-remitting MS, and the median disease duration was seven years. About 90 % judged
the website clear, understandable, useful, and easy to navigate. Ninety percent of people with MS and family
members would recommend it to others. Sixty-two percent reported they felt confident in making decisions on
interferons-β after reading the website.
Conclusions: The model was judged clear and useful. It could be adapted to other topics and diseases. Clinicians may
find it useful in their relationship with patients.
Keywords: Multiple sclerosis, Consumer health information, Internet, Information dissemination, Patient information
needs
Background
"I think there are too many confusing things on the
Internet. I don’t know how much to trust of the
information that I find. I need true, easy-to understand
health information that is useful to meet my needs".
(A person with multiple sclerosis participating in the
IN-DEEP focus group)
People with multiple sclerosis (MS) are mainly young
adults, who are increasingly using the Internet for MS-
related information. While neurologists or general practi-
tioners remain the principal or at least the most trusted
source of information for most people, the Internet is
often used to supplement their advice. People with MS
use the Internet to search for health information, stay
abreast of research, check claims to treatment benefits
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and adverse effects reported in the media and social net-
works [1–3].
A search on Google® (in English) in June, 5th 2015 using
the search term “multiple sclerosis” retrieved 23.4 million
links. From this huge amount of information, people need
to know how to assess the relevance of the information
and how it relates to them personally [4–6]. In a recent
study exploring the online health information needs and
barriers for people with chronic health conditions, partici-
pants complained of differences in the information from
different online sources as a recurrent difficulty, and
stated their desire for health professionals to play a role in
guiding them to find relevant and reliable online health in-
formation [7]. For people with MS to self-manage their
condition, information has to be of high quality, in plain
language, from independent sources, and based on reliable
and up-to-date evidence [1, 8–11].
The Integrating and Deriving Evidence, Experiences and
Preferences (IN-DEEP) project is an Italian-Australian col-
laboration developing two parallel projects to explore how
people with MS integrate health information they find on
the Internet with their needs, experiences, preferences and
values, and how these factors could be incorporated into
an online source of evidence-based information that was
accessible and meaningful to them and to family members
of people with MS [12]. It is an informational intervention
aimed to provide qualified information through the web,
to support the decision-making of people with MS with
clinicians. A four-stage process was used: first, health in-
formation needs were assessed through focus groups with
people with MS and family members led by a psychologist
[13, 14]; second, a template was developed presenting
evidence-based health information; third, the template
was implemented on the web and fourth, an online survey
was conducted to assess this web-based resource (Fig. 1).
Most of the people with MS and family members who
were involved in the focus groups during the first phase of
the Italian IN-DEEP project [13] reported difficulty navi-
gating through the mass of Internet data, in understanding
and evaluating quality and reliability of web information.
They said that web information often does not cover their
information needs or is inappropriate. There was a general
perception that good quality independent web information
is lacking. Even so, participants concluded that the
Internet was useful for people with MS. Their information
needs covered comprehensive communication of diagno-
sis, prognosis, benefit and adverse events of treatments,
and new drugs, gradually changing over the course of
the disease.
As reported in the literature, informational interven-
tions aimed at improving health literacy, in conjunction
with medical advice, can improve people’s knowledge,
symptom management and treatment adherence, reduce
anxiety, and increase a sense of empowerment. In par-
ticular, websites have beneficial effects on self-efficacy
and health behavior [15].
This paper describes the development of the Italian
IN-DEEP website and its assessment through an online
survey.
Methods
The project was a collaboration between the Cochrane
Multiple Sclerosis Group - Fondazione IRCCS Istituto
Neurologico “Carlo Besta”, Milan, IRCCS- Istituto di
Ricerche Farmacologiche “Mario Negri” Milan, the
Centre for Health Communication and Participation, La
Trobe University, Melbourne, and Italian and Australian
MS societies. It was approved by the Faculty of Health
Sciences Human Research Ethics Committee of La
Trobe University, Australia, and the Ethics Committee
of the Fondazione IRCCS Istituto Neurologico Carlo
Besta, Milan, Italy.
The project’s advisory committee included neurologists,
people with MS, experts in health literacy and communi-
cation and representatives of the Italian MS society. All
the phases of the project were discussed and shared with
the advisory committee.
Fig. 1 The steps of the IN-DEEP project
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The website
The website was developed through four main phases.
1. Development of a template
The purpose, structure and type of information
covered were decided on the basis of the focus group
findings [13] and the literature available [16–18] and
then discussed with the advisory committee. The first
topic was treatment with interferons-β (IFNs) for
people with relapsing-remitting MS (RR-MS). It was
selected as a first example to test the information
model considering that IFNs are used widely in clinical
practice and relevant scientific literature is available.
People with MS also asked for personal stories,
considered useful to convey and reinforce the
messages and translate them into daily life [13]. A
convenience sample of personal stories of people
with MS was collected by the neurologists involved
in the advisory committee. The stories were based
on three questions: 1. What was the effect of being
diagnosed with multiple sclerosis in your personal
experience? 2. Which questions did you ask yourself
to decide about taking interferon? Which
information did you need and look for? 3. How has
been your daily life taking interferon? Did interferon
therapy change your life?
The stories-literally reported-accompany the main
body of the website as an insight of patients voice
on their personal experience using interferon, and
the decision process to take it in terms of information
needs.
2. Review panels with people with MS
The structure of the template, content, layout and
wording were discussed with people with MS and
communication experts. Cochrane reviews were
used as the main evidence-based source for IFNs
benefit and short-term adverse events [19]. Information
on medium and long-term adverse events, not available
from randomised trials included in the Cochrane
reviews, was extracted from other sources, after
checking the quality of primary studies. Layout and
format for presenting benefits and harms of IFNs
were first developed on the basis of the literature
[20–22] then discussed in face-to-face interviews
with people with MS (n.9).
3. Website development and pilot testing
The final draft was adapted for the web and put
online for a short pre-test phase, whereby it was
pilot tested with a convenience sample of four
clinicians, three people with MS, four experts in
communication and web design and three lay people.
4. Website revisions and uploading
The final version was hosted on the website of the
Fondazione IRCCS Istituto Neurologico “Carlo
Besta”, Milan, Italy [23] and launched at the end of
October 2012.
The survey
The website was evaluated using an online survey pro-
moted through a press release, articles on the websites
and newsletters of the partners of the project, invitations
by e-mail, lay press articles, and presentations at meet-
ings reaching the general public, representatives of
patient and citizen associations, people with MS, clini-
cians, and researchers.
The 29-item questionnaire was informed by relevant
literature [17, 18]; before being reviewed by the advis-
ory committee and refined again after pilot testing (see
Additional file 1).
General questions were directed to all respondents, ask-
ing if the language and wording were clear, the contents
easy to understand, the information useful, and the web-
site easy to navigate. Specific questions directed to people
with MS and family members only related to risks and
benefits of IFNs treatment in RR-MS, satisfaction with the
online resource, whether it met respondents’ needs, and
its usefulness in making decisions about therapy. The sur-
vey was open for 4 months (November 2012 to February
2013) and participation was anonymous. Information
about the project and the survey- i.e., length of time of the
survey, which data were stored and where, the anonymity
of responses, who the investigators were, the purpose of
the study– was reported in the IN-DEEP section “About
us” and on the page hosting the online survey. Filling the
questionnaire was considered an implied consent to par-
ticipate to the survey.
Statistical analyses
Demographic and clinical characteristics of the sample
were analysed as percentages for categorical data, means
with standard deviations and medians with the corre-
sponding range for continuous variables, and by group
(people with MS, family members and others). The distri-
bution of the sample’s answers regarding language and
wording, comprehensibility of contents, usefulness of in-
formation – in general and specific for risks and benefits
of IFNs in RR-MS-and ease of web navigation is reported.
Results
The website
Considering that the information needs of people with MS
gradually change over the course of the disease [13, 14] the
website reflected preferences for information layered in
three levels- “in short” “in detail”, “to know more” (Fig. 2a).
Benefits of IFNs were reported in the three levels of detail,
with a few phrases in the section “in short”, numerical data
and graphs in the section “in detail”, and information about
the sources in “to know more” section. Bar graphs were
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used to illustrate numerical data of the IFNs benefits
(Fig. 2b), as they were considered clearer than other
layouts (e.g., icons) by the people with MS who were
interviewed. Harms were reported in a table divided by
frequency, without detailed numerical data, and by type
of IFN, i.e., Avonex, Rebif and Betaferon.
The need for qualified information expressed by the
focus groups was addressed by selecting evidence-based
sources of information where available, and citing the
sources linked to a methodological section explaining
the strength of evidence of different types of studies
(e.g., randomized controlled trials, systematic reviews).
Two sections called “what we know for sure” and “what
we do not know for sure yet” distinguished information
from strong evidence-based sources (short-term bene-
fits) from the areas of uncertainty still present in the
literature (mean long-term effects and when to give up
IFNs). Information on the long-term adverse effects of
IFNs, a topic raised by people with MS in the focus
groups and the working group, was extracted from
sources such as European Medicines Agency (EMA) re-
ports [24–26] and the Micromedex database [27], and
checked against primary studies.
The difficulties in assessing the quality of web-based
health information arising from the focus groups sug-
gested the need for educational tools such as a glossary
and tools to critically assess health information websites
and health information in general (“Misura-siti”, “Mis-
ura-informazione”) [28].
A section was dedicated to the personal stories of people
with MS related to the topic covered (e.g., “how I decided
to start treatment with IFN” or “my experience with IFN
treatment”). To address people with MS’ need to translate
online information to their own condition, a section called
“Is this information useful for me?” described the partici-
pants in clinical trials with IFNs and explained how their
characteristics can be applied generally. A list of questions
to ask to their neurologist, and practical information on
IFNs treatment (e.g., how to injections, to bring it medica-
tion on flights) was also provided.
The survey
In total, 555 participants started the survey, and 433
(70 %) completed the survey in full.
Of 555 web accesses, 425 were from people with MS
or family members and 130 from the general population.
Survey profile is reported in Fig. 3. Clinical and demo-
graphic characteristics of participants who only provided
demographic data were similar to those who completed
a part or all of the questionnaire (data not shown). In
all, 433 questionnaires were analysed (Table 1).
Most were RR-MS, the duration of disease varied from
0 to 32 years (median 7). More than two third were fe-
males, with a mean age of 45 years. More than a half
lived in small towns in northern Italy. A high proportion
had a high school diploma or over and two-thirds were
employed. No significant difference emerged in clinical
characteristics (respondent people with MS compared to
people with MS relatives of respondent family members)
or other main characteristics (people with MS, family
members, general population).
No significant differences in the distribution of an-
swers were observed by group for the general questions
aimed at the overall respondents (people with MS, fam-
ily members and general population) nor for specific
questions aimed at people with MS and family members
(data not shown).
Table 2 illustrates the perception of the website in
terms of plain language, comprehensibility of contents,
usefulness of information, and ease of navigation. Most
of the respondents gave positive judgments. Two percent
of respondents or less gave negative answers.
The three-level data reporting (“in short” “in detail” “to
know more”-Fig. 2a) was judged to be extremely useful in
order to understand information by 80 % of respondents.
In addition, 90 % said they would recommend the IN-
Fig. 2 a IN-DEEP home page. b Graphic presentation of a selection
of benefits of interferons
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DEEP website to people with MS (8 % responded “don’t
know” and 2 % “no”).
Most people with MS and family members considered
the information on benefits and harms of IFNs really/ex-
tremely useful and their graphic presentations very clear
(75 %) and easy to understand, while 6 % considered the
benefits, and 4 % the harms not clear. Twenty-nine per-
cent reported they were somewhat and 62 % really/ex-
tremely confident in making decisions about IFNs
therapy (Table 2).
Information in the section “to know more”, dedicated
to methodological aspects of studies, and in the glossary
was judged very useful and clear by people with MS and
family members (more than 85 % of really/extremely
and less than 3 % of no/not really).
In addition, 79 % of people with MS and family mem-
bers answered that the IN-DEEP online resource met their
information needs, 17 % moderately and only 5 % no/not
really. Free comments frequently mentioned that people
with MS and family members wanted to find other infor-
mation on the disease (causes, risk factors, diagnostic
tests, prognosis), on other MS forms and on other in
treatments used (data not shown).
Discussion
The IN-DEEP website is shaped on the needs and feed-
back of people with MS and family members and is
structured in multiple levels of depth so the reader can
decide how much and what kind of information to read.
It represents an information model that fosters an active
role for people with MS and family members in search-
ing for information to make healthcare decisions. The
principles of this model are summarized as follows: de-
veloping the structure and contents starting from the
needs of people with MS; providing multiple-level
evidence-based information with words, numbers and
pictures; citing the sources and describing their quality;
presenting methodological information and tools to crit-
ically appraise health information; presenting tools to
apply the information to the personal condition of the
reader, including personal stories. Most of these princi-
ples reflect the criteria for an evidence-based informa-
tion for patients reported in the literature [16].
As reported in a recent Cochrane review [29], informa-
tional interventions for people with MS are various, cover
different topics with various approaches and outcomes.
They seem to increase the knowledge of people with MS
about topics related to the disease, without conclusive re-
sults on decision making and quality of life. We assessed
the IN-DEEP website in terms of comprehensibility and
usefulness, asking people with MS if they would have used
it in making decisions and if it responded to their needs.
Most respondents judged it clear and useful. The overall
sample reported positive judgments, with almost always at
least 80 % of high and very high and no more than 5 % of
low and very low opinions. The majority reported they
would recommend the IN-DEEP website to others, but a
few found it less useful to make decisions. One reason
could be that some topics were not covered. People with
MS asked for plain information about drug comparisons,
new treatments and diagnostic test results, not yet covered
by the IN-DEEP website. The other reason could be that re-
spondents rely on the neurologist to make decisions related
to therapies. Free-text comments included, “the decision
Fig. 3 Flow-chart
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about interferon treatment is made by the neurologist. It is
a proposal which patients can complain about: medical ex-
pertise is different from information”; and “for this kind of
delicate decision I prefer to trust the judgment of the
neurologist, within a good doctor-patient relationship based
on trust”. The relationship with a trusted neurologist is the
first reference point for decisions. This is in line with the
findings of an Italian study about the attitudes of people
Table 1 Clinical and demographic characteristics of the sample
People with MS Family members of people with MS Other Overall
(276) (68) (89) (433)
n. (%) n. (%) n. (%) n. (%)
Diagnosis
Primary progressive 12 (5) 3 (7) - 15 (5)
Secondary progressive 32 (13) 13 (31) - 45 (16)
Relapsing remitting 203 (82) 26 (62) - 229 (79)
Missing data 29 26 - 55
Duration of disease from onset of symptoms (years)
Mean ± SD 9 ± 8 9 ± 9 - 9 ± 8
Median (range) 7 (0–32) 6 (0–32) - 6 (0–32)
Missing data 0 4 - 4
Sex
Female 192 (70) 48 (71) 63 (71) 303 (70)
Male 84 (30) 20 (29) 26 (29) 130 (30)
Age (years)
Mean ± SD 43 ± 11 45 ± 12 49 ± 13 45 ± 12
Median (range) 43 (2072) 45 (21–72) 50 (23–76) 45 (20–76)
Area of residence
Northern Italy 138 (50) 42 (62) 58 (66) 238 (55)
Central Italy 72 (26) 22 (16) 15 (17) 98 (23)
South and islands 65 (24) 15 (22) 15 (17) 95 (22)
Missing data 1 0 1 2
Size of places of residence
< 5000 inhabitants 49 (18) 16 (24) 10 (11) 75 (17)
5000–50,000 inhabitants 116 (42) 22 (32) 23 (26) 161 (37)
50,000–100,000 inhabitants 30 (11) 14 (21) 7 (8) 51 (12)
100,000–500,000 inhabitants 42 (15) 5 (7) 13 (15) 60 (14)
> 500,000 inhabitants 38 (14) 11 (16) 35 (40) 84 (19)
Missing data 1 0 1 2
Education
Primary school diploma 2 (1) 2 (3) 1 (1) 5 (1)
Middle school diploma 30 (11) 10 (15) 14 (16) 54 (12)
High school diploma or higher 244 (88) 56 (82) 74 (83) 374 (87)
Employment
Employed 185 (67) 50 (74) 48 (54) 283 (65)
Retired 33 (12) 9 (13) 26 (29) 68 (16)
Student 10 (4) 1 (1) 2 (2) 13 (3)
Homemaker 22 (8) 1 (1) 8 (9) 31 (7)
Unemployed looking for work 26 (9) 7 (10) 5 (6) 38 (9)
Abbreviations: MS multiple sclerosis
Colombo et al. BMC Neurology  (2016) 16:30 Page 6 of 9
with MS towards medical decision making in clinical set-
ting, showing that the majority of people involved preferred
a collaborative role (decision with neurologist), followed by
a passive role (decision by neurologist), and finally by an ac-
tive one (have the last say) [30].
We found in earlier focus groups that patients refer to
the web without telling the neurologist when their infor-
mation needs remain unanswered, either because of the
lack of time during a visit or the neurologist’s difficulty
in grasping the patients’ requests. A recent study [31]
showed that Italian MS physicians need more training
on shared decision making skills, to understand patient
preferences for reception of information and involve-
ment in health decisions. We suggest that neurologists
may find the IN-DEEP website a useful tool to foster a
dialogue with patients about the therapy.
We drew together evidence-based MS information with
the needs of people with MS: the challenge was to match
people with MS’ information needs with the best sources
available from research. The mismatch between patients
needs and research is well documented [32] and is an
issue also in the dissemination of the information. We
tried to tackle by it including information from various
sources clearly explaining their limits and the related un-
certainty. As reported in literature [33], people with MS
are not scared by complex evidence-based information
showing the uncertainties of data.
Answering the information needs of patients in a situ-
ation of uncertainty is a difficult task even for clinicians
during the visit. This is why clinicians may find a web-
based resource that was developed starting from people
with MS’ needs and with their cooperation helpful [33,
34]. Time constraints often limit the amount and kind
of information that clinicians provide to patients. A web-
site such as IN-DEEP could be suggested by clinicians as
a source of high-quality research about treatment for
MS, that is potentially useful also to increase patients’
critical appraisal skills. The application of the IN-DEEP
website in this context should be implemented and
assessed widening the topics covered.
Strengths and limitations
Considering the lack of data about long term adverse ef-
fects of interferons from clinical trials included in the
Cochrane review, we collected data from the EMA re-
ports and the Micromedex database in order to answer
people with MS’ information needs, indicating the meth-
odological limits of these sources.
As for the survey, the sample was representative of
people with MS and the population distribution of Ital-
ians, as reported in the literature [35].
We lost 20 % of the sample who only provided demo-
graphic data, but we found no differences in the demo-
graphic and clinical characteristics of this sample compared
to the other responders, suggesting the results are robust.
The level of education of respondents to the survey was
high, compared to that reported by the Italian National In-
stitute of Statistics (ISTAT) [36]. According to the ISTAT
report, in Italy 58 % of people, from 25 to 64 years of age,
have a high school diploma or over, with larger propor-
tions in central (63.7 %) and northern (61.3 %) Italy. In
our survey, 87 % of respondents had corresponding simi-
lar level of education, with no significant difference by re-
gion [data not shown]. A high level of education of
respondents was expected, since this was an online survey
[37, 38] and Internet use is driven partly by educational
level [39] but the generalisability of the results, especially
regarding the readability and understandability of the in-
formation, need to be specifically assessed with people
with lower education levels.
Table 2 Survey findings. Selection of items
No/Not really Somewhat Really/extremely
n. (%) n. (%) n. (%)
Overall sample n.433
Is the website easy to navigate? 8 (2) 23 (5) 387 (93)
Is the information easy to understand? 3 (1) 54 (12) 376 (87)
Is the information useful? 9 (2) 59 (14) 365 (84)
Persons with MS and family members n. 344a
Are the benefits of interferon clear? 18 (6) 57 (19) 229 (75)
Are the harms of interferon clear? 13 (4) 36 (12) 255 (84)
Are graphic presentations of IFN benefits easy to understand? 8 (3 %) 54 (18 %) 242 (79 %)
Are tables of IFN harms easy to understand? 8 (3 %) 37 (12 %) 259 (85 %)
Is the information on benefits and harms useful? 11 (4) 59 (21) 216 (75)
Are you more confident in making decisions about interferon therapy? 26 (9) 82 (29) 178 (62)
Abbreviations: IFN interferon, MS multiple sclerosis
aThe sum does not add up to the total because of some missing values. The percentages are calculated on the total responders to the single question
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Since the aim of the survey was to test a web-based
model, results refer to persons who used the internet.
This is in line with the increasing use of the web by
people with MS to search for information related to the
disease.
Information on interferons presented in the website is
one piece of the information jigsaw. The personal stories
were added as an example of another piece of information,
i.e., patients’ preferences and experiences. In the frame-
work of the IN-DEEP website, we included also the meth-
odological section and the section dealing with the critical
appraisal of health information, both underlying the differ-
ent levels of certainty deriving from different kind of
sources (case reports, controlled trials, randomized con-
trolled trials, systematic reviews…).
Finally, interferons for relapsing-remitting multiple
sclerosis are the first example used to test the informa-
tion model. Other topics are under development.
Conclusions
The IN-DEEP website meets the need of people with
MS for good-quality information, and we shall use this
model as a basis for developing further topics of rele-
vance to them.
The IN-DEEP web-based model could be adapted to
other diseases and conditions, in the framework of col-
laboration among clinicians, researchers, experts in com-
munication and patient associations.
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